Who
Martin Mackay
Director
Company insider
Files Form 4 as: Director, Charles River Laboratories International; Director, Kailera Therapeutics; Executive Chairman, Rallybio; Director, SpringWorks Therapeutics; Director, 5:01 Acquisition; EVP & Global Head of R&D, Alexion Pharmaceuticals; Senior Vice President, Pfizer.
In numbers
- Trades disclosed
- 165
- Buys
- 2
- Sells
- 16
- Bought
- $103K
- Sold
- $18.4M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 31 Oct 2007
- Last trade
- 8 May 2026
- Last filed
- 11 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 May 2026filed 11 May 2026 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $255K1,438 at $177.62 | filing |
| 8 May 2026filed 11 May 2026 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $250K1,407 at $177.62 | filing |
| 8 May 2026filed 11 May 2026 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $255K1,438 at $177.62 | filing |
| 8 May 2026filed 11 May 2026 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $250K1,407 at $177.62 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | $65K18,055 at $3.60 | filing |
| 18 Feb 2026filed 20 Feb 2026 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | $65K18,055 at $3.60 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —29,445 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeutics | SEC FORM 4 Code D | —20,023 | filing |
| 21 May 2025filed 23 May 2025 | CRL Charles River Laboratories Internationaloption or derivative · Life-science tools | SEC FORM 4 Code A | $280K2,076 at $134.98 | filing |
| 21 May 2025filed 23 May 2025 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $128K946 at $134.98 | filing |
| 21 May 2025filed 23 May 2025 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $110K815 at $134.98 | filing |
| 14 May 2025filed 15 May 2025 | SpringWorks Therapeutics | SEC FORM 4 Code A | —10,060 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | $65K92,857 at $0.70 | filing |
| 29 Jul 2024filed 30 Jul 2024 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code A | —29,445 at $0.00 | filing |
| 29 Jul 2024filed 30 Jul 2024 | SpringWorks Therapeutics | SEC FORM 4 Code A | —9,963 at $0.00 | filing |
| 13 May 2024filed 15 May 2024 | CRL Charles River Laboratories Internationaloption or derivative · Life-science tools | SEC FORM 4 Code A | $299K1,311 at $228.41 | filing |
| 13 May 2024filed 15 May 2024 | CRL Charles River Laboratories InternationalLife-science tools | SEC FORM 4 Code A | $128K559 at $228.41 | filing |
News
Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)RLYB · dailypolitical.com · 14 Oct 2026Financial Analysis: NewAmsterdam Pharma (NASDAQ:NAMS) versus Rallybio (NASDAQ:RLYB)RLYB · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Martin Mackay; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.